Thursday 16 October, 2025
Introduction During the covid-19 pandemic, a large number of clinical prognostic scores have been proposed and evaluated for hospitalized patients,…
Read moreAbstracts
Individual dynamic predictions in joint analysis for nonlinear marker evolution and competing risk data: application on patients admitted in Intensive Care Unit for sepsis
Thursday 16 October, 2025
Background: Joint models of longitudinal process and time to event data have recently gained attention specially for providing individualized dynamic…
Read moreExtending the R open-source saemix package: a new tool for parametric joint models
Thursday 16 October, 2025
Introduction: Joint modeling of longitudinal and time-to-event data has gained attention over recent years with extensive developments [1,2]. When the…
Read moreQuantitative comparisons of Progressive Supranuclear Palsy rating scales versions using Item Response Theory modeling
Thursday 16 October, 2025
Background: Progressive Supranuclear Palsy (PSP) is a neurodegenerative late-onset disease that is challenging in terms of assessment. The Progressive Supranuclear…
Read morePopulation pharmacokinetic/pharmacodynamic modelling of the psychedelic experience induced by N,N-dimethyltryptamine
Thursday 16 October, 2025
Introduction/Objectives: N,N-dimethyltryptamine (DMT) is a naturally occurring, psychedelic compound that is believed to have potential as a treatment option in…
Read moreEvaluation and Optimization of Model-based Translations in Oncology – From Xenografts to RECIST
Thursday 16 October, 2025
Objectives: Evaluate currently used translational methods in oncology using preclinical (xenograft data) and clinical data (response rate based on RECIST…
Read moreModel-based Prediction of Progression-Free Survival for Combination Therapies in Oncology
Thursday 16 October, 2025
Objectives: Extend a joint modeling approach for predicting progression-free survival (PFS) for monotherapies [1] to combination therapies. Test the model’s…
Read moreInfluence of body composition on the pharmacokinetics of monoclonal antibodies : example of cetuximab and bevacizumab
Thursday 16 October, 2025
Introduction : The exposure-response relationship of monoclonal antibodies (mAbs) in oncology is complex and may be blurred by several confounding factors….
Read moreTarget-mediated pharmacokinetics of cetuximab: target occupancy influences progression-free survival
Thursday 16 October, 2025
Introduction: Cetuximab (ERBITUX®), an anti-EGFR monoclonal IgG1 antibody, has been approved for the treatment of metastatic colorectal cancer (mCRC). The…
Read moreTarget-response relationship of bevacizumab may be more relevant than exposure-response – a target-mediated drug disposition (TMDD) model
Thursday 16 October, 2025
Introduction: Bevacizumab (BV), an anti-angiogenic monoclonal antibody targeting vascular endothelial growth factor (VEGF), has been approved for the treatment of metastatic…
Read more